Coste MP, López SO

Language: Spanish
References: 18
Page: 1-7
PDF size: 662.70 Kb.

ABSTRACT

Graves’ or thyroid ophthalmopathy is a condition confined to the orbit in which an immune reaction to an autoantigen, which is probably the TSH receptor, causes an inflammatory reaction affecting the extraocular muscles and orbital tissue1. Just a small percentage of patients with ophtalmophaty are euthyroid and even a smaller percentage, have unilateral or asymmetrical involvement. The nat-ural history of unilateral TAO is unknown2. This is a case report and review of an euthyroid patient with unilateral thyroid ophthalmopathy.

REFERENCES

1. Gómez JM. Valoración y tratamiento de la oftalmopatía de Graves. Endocrinol Nutr. 2004;51:60.

2. Ch. Daumerie, Th. Duprez, A. Boschi. Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitop-athy European Journal of Internal Med-icine 19 (2008) 531–536.

3. Bahn R. Graves’ Ophthalmopathy. NEJM 362;8, 2010.

4. Kymberly P, Cockerham, Stephanie SC. Thyroid eye disease. Neurol Clin. 2010;28:729---755.

5. N Kamminga, N M Jansonius, J W R Pott, et al. Unilateral proptosis: the role of medical history. Br J Ophthalmol. 2003 Mar; 87(3): 370–371.

6. Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmo-pathy in an incidence cohort. Am J Oph-thalmol 1996; 121:426.

7. Brownlie BEW, Newton OAG, Singh SP. Ophthalmopathy associated with primary hypothyroidism. Acta Endo-crinol 1975;79:691–699.

8. K Cockerham, S Chan. Thyroid Eye Dis-ease. Neurol Clin 28 (2010) 729–755.

9. Bartalena L, Tanda ML. Graves’ Op-hthalmopathy. NEJM 360;10, 2009.

10. Kendler DL, Lippa J, Rootman J. The in-itial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol 1993;111:197–201.

11. Stan M, Bahn Rebecca. Risk Factors for Development or Deterioration of Graves´ Ophtalmopathy. Thyroid, Vol 2o, Number 7, 2010.

12. Burch HB, Wartofsky L. Graves’ oph-thalmopathy: current concepts regard-ing pathogenesis and management. En-docr Rev 1993;14:747–793.

13. Fernández RV. Manifestaciones clínicas de la oftalmopatía tiroidea. An Sist Sanit Navar. 2008;31 Suppl. 3:45---56.

14. Perez JV, Coloma JE, Prada MC. Orbi-topatía tiroidea (fisiopatología, diagnós-tico y tratamiento). Arch Soc Esp Of-talmol. 2003;78:407---431.

15. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996;45:477-481.

16. Bartalena L, Marcocci C, Bogazzi F, et. al. Relation between therapy for hyper-thyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998;338: 73-78.

17. Consensus statement of the European Group on Graves’ Orbitopathy (EU-GOGO) on management of Graves’ or-bitopathy. Thyroid 2008;18:333-346.

18. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves’ orbitopathy: randomized pla-cebo-controlled study. Lancet 2000;355:1505-1509.